News & Updates
Filter by Specialty:
Exercise, Mediterranean diet remain key against MASLD
A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.
Exercise, Mediterranean diet remain key against MASLD
21 Jun 2024
Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis
Treatment with obeticholic acid (OCA) improves clinical outcome in patients with precirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH), with a reduction in histological progression to cirrhosis seen in those receiving the 25-mg dose, as seen in the final results of the REGENERATE study.
Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis
20 Jun 2024
Resmetirom proves efficacy in NASH patients with or without MetALD
Patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis treated with resmetirom achieve NASH resolution with no fibrosis worsening (NR) or ≥1-stage fibrosis improvement with no worsening of the NAS score (FI), according to the results of the ongoing MAESTRO-NASH study.
Resmetirom proves efficacy in NASH patients with or without MetALD
20 Jun 2024
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
